Welcome to our dedicated page for Septerna SEC filings (Ticker: SEPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Septerna, Inc. (Nasdaq: SEPN) SEC filings, offering detailed regulatory disclosures about the company’s operations as a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery. As an issuer with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC or The Nasdaq Global Market, Septerna files current and periodic reports that describe its business, governance and financial condition.
Septerna’s Form 8-K filings frequently cover material events such as quarterly financial results and business highlights, including revenue, research and development expenses, general and administrative expenses, net income or loss, cash and marketable securities, working capital, total assets, total liabilities and stockholders’ equity. Other 8-Ks disclose collaboration agreements, such as the global collaboration and license agreement with Novo Nordisk A/S, leadership and board appointments, executive role changes, investor presentations and annual meeting voting results.
Through its SEC filings, Septerna also reports on matters like director elections, committee assignments, non-employee director compensation, and submission of matters to a vote of stockholders. These documents provide insight into the company’s corporate governance framework, including the composition of its board and committees and the outcomes of shareholder votes.
On Stock Titan, Septerna’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy filings, so readers can quickly understand the implications of new 8-Ks and other reports without reviewing every page. Users can review historical filings to track trends in Septerna’s financials, follow the evolution of its collaborations and governance, and monitor ongoing disclosure about its GPCR-focused pipeline and clinical-stage programs.
Septerna, Inc. director Bernard Coulie received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $37.34 per share and expire on June 25, 2036. All 15,000 options vest in full on the earlier of June 26, 2027 or the date of Septerna’s next annual stockholders’ meeting, as long as he continues serving the company through that date. This is a compensation-related award, not an open-market share purchase or sale.
Septerna, Inc. director Jeffrey K. Tong received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $37.34 per share and expire on June 25, 2036. Following this grant, Tong holds stock options on 15,000 shares directly.
According to the terms, the 15,000 option shares vest in full on the earlier of June 26, 2027 or the date of Septerna’s next annual stockholder meeting, provided Tong continues serving the company through the vesting date.
Septerna, Inc. director Keith Michael Gottesdiener received a grant of stock options covering 11,260 shares of common stock. The options carry an exercise price of $37.34 per share and expire on June 25, 2036.
These options vest in full on the earlier of June 26, 2027 or the date of Septerna’s next annual meeting of stockholders, as long as he continues serving the company through that date. After this grant, he holds 11,260 stock options directly.
Septerna, Inc. director Alan Ezekowitz received a grant of stock options as part of his compensation. The award covers 15,000 options to acquire Septerna common stock at an exercise price of $37.34 per share, with the option term running until June 25, 2036.
These options vest in full on the earlier of June 26, 2027 or the date of Septerna’s next annual meeting of stockholders, provided he continues to serve the company through the vesting date. Following this grant, his directly held option position from this award totals 15,000 shares underlying common stock.
Septerna, Inc. reported that director Jake Simson received a grant of stock options covering 15,000 shares of common stock at an exercise price of $37.34 per share. The options vest in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided he continues to serve until that date.
Under an arrangement with RA Capital Management, L.P., Simson holds this option for the benefit of R.A. Capital Healthcare Fund, L.P. and R.A. Capital Nexus Fund III, L.P. Any net cash or stock from exercising the option must be turned over to the adviser to offset advisory fees, and Simson disclaims beneficial ownership of the option and underlying shares.
Septerna, Inc. held its 2026 annual meeting of stockholders on June 26, 2026. Stockholders elected Shalini Sharp, M.B.A. and Jake Simson, Ph.D. as Class II directors to serve three-year terms ending at the 2029 annual meeting and until their successors are elected and qualified or earlier departure.
Sharp received 33,732,317 votes for and 5,808,264 votes withheld, while Simson received 33,716,857 votes for and 5,823,724 votes withheld. Stockholders also ratified Ernst & Young LLP as Septerna’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 41,207,237 votes for, 4,008 against, and 298,811 abstentions.
SEPN Rule 144 notice: The filing lists proposed transactions in Common stock under an Employee Stock Purchase Plan and a Rule 144 notice dated 06/26/2026. It shows a reported sale by JAE KIM of 94,339 shares on 06/22/2026 for $3,326,119.56. The excerpt also lists plan-related entries dated 10/31/2025 (1,198 shares) and 04/30/2026 (1,240 shares).
Septerna, Inc. SVP of Drug Discovery Daniel D. Long reported option exercises and share sales in SEPN stock. On June 22, 2026, he exercised options for 4,471 shares at $11.70 per share and 10,529 shares at $2.76 per share, converting them into common stock.
On the same date, he sold 7,000 shares at a weighted average price of $35.9687 and 8,000 shares at $35.1001 in open-market transactions under a pre-arranged Rule 10b5-1 sales plan. After these transactions, he directly holds 96,412 shares of common stock.